share_log

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim集團以買入評級啓動對NeuroBO製藥的報道,宣佈目標股價爲10美元
Benzinga ·  05/08 10:08

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $10.

Maxim集團分析師傑森·麥卡錫以買入評級啓動了對NeuroBo Pharmicals(納斯達克股票代碼:NRBO)的報道,並宣佈目標股價爲10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論